TrialCancer science2020

Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

Makoto Nishio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.